Press Releases                                              

Will Goldman Sachs' (NYSE: GS) Trading Unit Sale Make The Difference?
A recent CNBC report suggested that Goldman Sachs' (NYSE: GS) was looking to sell its proprietary trading unit and the stock has responded with further gains after having bottomed in June.



Chart Courtesy of StockCharts.com


The market liked the news of the potential sale of the trading unit. For one thing, it's that trading unit that seems to have gotten Goldman into trouble over its recently settled issues with the SEC. The problem is that the trading unit makes a lot of money, which means that Goldman will have to rely on its other businesses, investment banking, money management and the administration of its vast holdings for its income.

It's hard to tell how much money will be leaving the door if and when the sale or spinoff of the unit takes place. But we suspect that a good deal of it will be doing so.

That leaves investors with the same set of questions that have dogged the company for the last few months. Is Goldman, now presumably without its big time trading unit, going to be the Goldman that Wall Street has looked upon to be a bellwether for the markets?

In this case, though, the company almost has to shed its trading unit. It is essentially a bank, after having taken TARP money, even though it paid it back. And since banks are being pressured to separate trading from banking, maybe Goldman is just getting ahead of the inevitable.

AT this point, though, Goldman shares are back above their 200-day moving average, just as the S & P 500 is poised to break out of its recent trading range. It's probably not a coincidence that the market is improving at the same time that shares of Goldman are starting to act much better.

Follow Dr. Duarte on Twitter

Make money if any market rises or falls, with a copy of "Market Timing For Dummies."

“Futures And Options For Dummies,” Dr. Duarte’s latest book is now available. The markets are responding to news and geopolitical developments like never before. In this environment, individual investors need to expand their investment horizons. "Futures And Options For Dummies " (John Wiley & Sons) has an excellent section on oil futures as well as the currency markets, while covering and expanding on the successful strategies in Doctor Duarte's other books. Order your copy today.

Doctor Joe Duarte's Market I.Q., offers subscribers a unique blend of intelligence, market commentary and trading strategy. Duarte's daily articles, and news summaries offer recommendations and analysis for ETFs, and individual stocks in the technology, health and biotechnology, and energy sectors. Doctor Duarte is a writer, and an emerging futurist, with a diverse background, and a growing audience. His combined expertise in health care, energy, and the effects of politics and global intelligence on the financial markets offer a unique blend of insight and information to thousands of active investors and political and intelligence aficionados around the world on a daily basis.

He is the author of four books: "Futures And Options For Dummies," "Successful Energy Sector Investing," "Successful Biotech Investing" and co-author of "After-Hours Trading Made Easy."

In early 2001 Dr. Duarte in "Successful Energy Sector Investing," correctly predicted that Venezuela's political problems could lead to an energy crisis in the United States.

In 2003, also Dr. Duarte was among the first to widely publicize the long-term friendship between French President Jacques Chirac and Saddam Hussein.

He has also appeared as a weekly guest on Market Mavens Radio, has logged appearances on KNX radio in Los Angeles, Financial Sense.com radio, and Wall Street Radio.

One of CNBC's original Market Mavens, Dr. Duarte has been writing about the financial markets since 1990.

His articles and commentary have been featured on CBS Marketwatch, Barron's, Smart Money, Medical Economics, and in Technical Analysis of Stocks and Commodities magazines.

In 2003, Doctor Duarte received second place, in the professional section, of the Medical Economics Investment Challenge with a 12-month return of 42%.




Joe-Duarte.com is independently operated and solely funded by subscriber fees. This web site and the content provided is meant for educational purposes only and is not a solicitation to buy or sell any securities or investments. All sources of information are believed to be accurate, or as otherwise stated. Dr. Duarte and the publishers, partners, and staff of Joe-Duarte.com have no financial interest in any of the sources used. For independent investment advice consult your financial advisor. The analysis and conclusions reached on Joe-Duarte.com are the sole property of Dr. Joe Duarte.